RE-VANA THERAPEUTICS
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections. Their delivery platforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, ... delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers. Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more. The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.
RE-VANA THERAPEUTICS
Industry:
Health Care Market Research Medical Therapeutics
Founded:
2015-01-01
Address:
Belfast, Belfast, United Kingdom
Country:
United Kingdom
Website Url:
http://www.re-vana.com
Total Employee:
1+
Status:
Closed
Contact:
L +44 28 9097 5814
Email Addresses:
[email protected]
Total Funding:
4.83 M USD
Technology used in webpage:
SPF Amazon ReCAPTCHA Amazon Virginia Region NameBright
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Advisors List
Current Employees Featured
Founder
Investors List
QUBIS
QUBIS investment in Seed Round - Re-Vana Therapeutics
Clarendon Fund Managers
Clarendon Fund Managers investment in Seed Round - Re-Vana Therapeutics
SyndicateRoom
SyndicateRoom investment in Seed Round - Re-Vana Therapeutics
Techstart Ventures
Techstart Ventures investment in Seed Round - Re-Vana Therapeutics
ExSight Ventures
ExSight Ventures investment in Seed Round - Re-Vana Therapeutics
InFocus Capital Partners
InFocus Capital Partners investment in Seed Round - Re-Vana Therapeutics
Visionary Venture Fund
Visionary Venture Fund investment in Seed Round - Re-Vana Therapeutics
Clarendon Fund Managers
Clarendon Fund Managers investment in Seed Round - Re-Vana Therapeutics
Techstart Ventures
Techstart Ventures investment in Seed Round - Re-Vana Therapeutics
MassChallenge
MassChallenge investment in Non Equity Assistance - Re-Vana Therapeutics
More informations about "Re-Vana Therapeutics"
Home - Re-Vana: Making Great Drugs Better
Re-Vana is developing sustained release ocular biologics. In addition, we can reduce the need for topical drug delivery.See details»
Re-Vana Therapeutics - Crunchbase Company Profile
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such …See details»
About Re-Vana - Re-Vana: Making Great Drugs Better
Management Team - Re-Vana: Making Great Drugs Better
As the Founder and CTO of Re-Vana Therapeutics, Prof. Thakur is committed to developing innovative long-acting drug delivery systems.See details»
Re-Vana Therapeutics - LinkedIn
Re-Vana Therapeutics is a venture-backed, pioneering therapeutics and ocular drug delivery company developing innovative sustained-release biologics to treat serious retinal diseases.See details»
Re-Vana Therapeutics - Funding, Financials, Valuation & Investors
Re-Vana Therapeutics is funded by 9 investors. Co-FundNI and QUBIS are the most recent investors. in funding over 4 rounds. Their latest funding was raised on Nov 30, 2022 from a …See details»
Re-Vana Therapeutics - VentureRadar
Re-Vana Therapeutics is an ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery …See details»
Re-Vana Therapeutics - Updates, News, Events, Signals & Triggers
Re-Vana Therapeutics may be growing as evidenced by a successful raise of $11.9 million in a Series A funding round in December 2022, which is a significant financial milestone for the …See details»
Re-Vana Therapeutics Company Profile 2024: Valuation, Funding ...
Jan 1, 2019 · Developer of a biodegradable drug delivery platform designed to address ophthalmic conditions. The company's biodegradable drug delivery platform offers tailored …See details»
Re-Vana Therapeutics raises $11.9m to boost eye disease treatment
Dec 1, 2022 · Belfast-based Re-Vana Therapeutics has raised $11.9m in Series A funding to develop its drug delivery technology for ocular diseases. The funding round was …See details»
Re-Vana - Products, Competitors, Financials, Employees, …
Re-Vana is a company focused on the development of sustained release ocular biologics in the pharmaceutical industry.See details»
Re-Vana Therapeutics Company Profile - Craft
Re-Vana Therapeutics is a company that develops a biodegradable drug delivery platform. It develops sustained-release ophthalmic therapeutics that can reduce the frequency of …See details»
Board of Directors - Re-Vana: Making Great Drugs Better
Michael O’Rourke, has been involved in “drug delivery” for over 30 years across Ophthalmology, Periodontal and Pulmonary markets including strategy development and global …See details»
RE-VANA THERAPEUTICS RAISES $11.9 MILLION IN SERIES A …
Nov 30, 2022 · Re-Vana is a technology spin-out from Queen's University, located in Belfast, Northern Ireland. The company is currently developing sustained release ophthalmic …See details»
Re-Vana Therapeutics raises $11.9 million in Series A financing for ...
Nov 30, 2022 · Re-Vana is a technology spin-out from Queen's University, located in Belfast, Northern Ireland. The company is currently developing sustained release ophthalmic …See details»
Re-Vana Therapeutics - Contacts, Employees, Board Members
Re-Vana Therapeutics has 7 current employee profiles, including CEO & Director Michael J. O'Rourke. Re-Vana Therapeutics has 8 board members and advisors, including Michael Nissen.See details»
Queen’s University spin-out Re-Vana Therapeutics raises $3.25m
Jun 3, 2020 · Re-Vana Therapeutics, a Queen's Univeristy Belfast spin-out focused on ocular diseases, has raised $3.25m in pre-Series A funding.See details»
Careers - Re-Vana: Making Great Drugs Better
Keep up-to-date with the latest Re-Vana news, publications and presentations. See what opportunities our company can offer. Learn more about our innovative technology. Find out …See details»
Re-Vana Therapeutics raises $11.9 million to advance ophthalmic ...
Dec 1, 2022 · Re-Vana is a technology spin-out from Queen's University, located in Belfast, Northern Ireland. The company is currently developing sustained release ophthalmic …See details»
Re-Vana Therapeutics Names New Members to the Executive Team
Mar 11, 2021 · Re-Vana is developing sustained release ophthalmic therapeutics that reduce the frequency of intravitreal injections required to treat a wide range of retinal diseases, including …See details»